


Cipla









Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.











Dear Colleague,

The field of Rheumatology is dynamic with constantly evolving diagnosis and treatment approaches. Regular updates are a must to stay ahead of the curve.

virtual e-RHECON in March 2021 garnered overwhelming response with your support and participation. With the aim of discussing and ideating on the latest develoPMents in the clinical arena of Rheumatology, we invite you to join the 2nd Virtual Summit organized by Arthritis & Rheumatic Diseases Foundation (ARDF) in collaboration with Cipla- "Mid-Year e-RHECON 2021", a unique blend of knowledge and experience 2nd held on 1st & October 2021 from sharing to be 6:30 PM to 9:15 PM.

This interesting program brings together international and national stalwarts along with young rheumatologists to provide a panoramic view of contemporaneous management practices and latest updates encompassing the spectrum of adult & paediatric rheumatic diseases.

Your participation at "Mid-Year e-RHECON 2021" is bound to make the program interesting, informative and interactive.

We look forward to your active contribution.

With kind regards,

Yours sincerely,

Dr. S. J. Gupta

Chair ARDF

Dr. Rohini Handa Secretary ARDF

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.











DAY 1: Friday, 1st October 2021



Prof. Philip J. Mease
MD
Clinical Professor,
University of Washington School of Medicine,
Director of Rheumatology Research,
Swedish Medical Center, Seattle, WA, USA

TIME: 06.35 PM - 07.00 PM
TOPIC: JAK-STAT Inhibition: Prospects in Ankylosing Spondylitis

Prof. Philip J. Mease, MD is a Clinical Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Center in Seattle, WA,USA. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease earned his undergraduate and medical degrees at Stanford University (Stanford, CA, USA). He then completed his residency in internal medicine and a fellowship in rheumatology at the University of Washington School of Medicine.

Dr Mease's research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA), rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia (FM), and osteoporosis. His research focuses on disease state, outcome measure development, and determining the efficacy and safety of emerging therapies for these conditions. His seminal 2000 Lancet paper established the efficacy of anti-tumour necrosis factor (TNF) therapy in PsA. He has authored over 500 journal articles and many hundreds of abstracts, book chapters, and edited textbooks on PsA and axial SpA (AxSpA). He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism.

He serves in an educational and advisory role for the US Food and Drug Administration(FDA) and is a member of the steering committee of the arthritis section of the International Consortium for Health Outcomes Measurement(ICHOM). He conducts disease state research in registries such as the Consortium of Rheumatology Researchers of North America (CORRONA), for which he is Director of the PsA–SpA arm. Dr Mease is a Master of the American College of Rheumatology (ACR) and has received its Medical Communicator of the Year Award for his teaching there and in the community. He is a Co-Chair of the ACR abstract review committee section on SpAand PsA and serves on the Voting Committee for the ACR-NPF (National Psoriasis Foundation) Psoriatic Arthritis treatment guidelines task force. He is also Co-Chair of the PsA task force of the NPF, which in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA.

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.















DAY 2: Saturday, 2nd October 2021



International Faculty Prof. Yoshikazu Nakaoka M.D. Ph.D.

Director, Department of Vascular Physiology, National Cerebral & Cardiovascular Center Research Institute, Japan

TIME: 06.35 PM - 07.00 PM **TOPIC**: Role of IL-6 inhibitors in Large Vessel Vasculitis

EDUCATION AND DEGREES:

Apr. 1987-Mar. 1991: Department of Biophysics and Biochemistry, Faculty of Science, University of Tokyo **B.A. Awarded (1991)**

Apr. 1991-Mar. 1992: Department of Biophysics and Biochemistry,

Graduate School of Science, University of Tokyo

Apr. 1992-Mar. 1996: Osaka University School of Medicine,

M.D. Awarded (1996)

Apr. 2000-Mar. 2004: Osaka University Graduate School of Medicine,

Ph.D. Awarded (2004)

PRESENT POST:

Director,

Department of Vascular Physiology

National Cerebral and Cardiovascular Center Research Institute.

Adjunct Professor at Department of Molecular Imaging in Cardiovascular Medicine

Osaka University Graduate School of Medicine

HONOURS AND AWARDS:

2006: Young Investigator's Award (Best prize), Japanese Society of Heart Failure

2008: Yaqi Award for Cardiovascular Biochemical Research, Japanese Circulation

Society

2014: Osaka University Presidential Awards for Encouragement

Selected Publications (*corresponding author) of 10 studies/trials

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.











FACULTY



Prof. Alakendu Ghosh Kolkata



Dr. Anand P. Rao Bangalore



Dr. Avinash Jain Jaipur



Dr. Banwari Sharma Jaipur



Dr. B. G. Dharmanand Bangalore



Dr. Debashish Danda Vellore



Dr. Himanshu Pathak Vadodara



Dr. Keerthi Talari Hyderabad



Dr. Manish Dugar Hyderabad



Dr. Manjari Agarwal Delhi



Dr. N. Raja Chennai



Dr. Nilesh Nolkha Mumbai



Dr. Padmanabha Shenoy Dr. Pradip Kumar Sarma Cochin



Guwahati



Dr. Ramesh Jois Bangalore



Dr. Prof. Rohini Handa Delhi

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.















Dr. Sanjiv Kapoor



Dr. Santosh Mandal Kolkata



Dr. S. J. Gupta Delhi



Dr. Sonal Mehra Delhi



Dr. T. Sathish Vellore



Dr. Uday Khopkar Mumbai



Dr. Vasant Nagvekar Mumbai



Dr. (Lt. General) Ved Chaturvedi New Delhi



Dr. Vignesh Pandiarajan Chandigarh



Dr. Vijay K. RaoBangalore



Dr. Vineeta ShobhaBangalore



Dr. Vishad ViswanathTrivandrum



Dr. Yojana Gokhale Mumbai

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.













DAY 1: Friday 1st October, 2021 Time 6.30 PM to 9.15 PM

6:30 PM - 6:35 PM Welcome by

Dr. Jaideep Gogtay

Chief Medical Officer- Cipla

Dr. S. J. GuptaChair ARDF

Session 1

Chairperson: Dr. Prof. Rohini Handa

6:35 PM - 7:00 PM JAK-STAT Inhibition: Prospects in

Ankylosing Spondylitis (AS)

Speaker: Prof. Philip J. Mease (USA)

7:00 PM - 7:05 PM Q & A

Chairperson: Dr. Prof. Rohini Handa

Session 2

Chairperson: Dr. B. G. Dharmanand

7:05 PM - 7:30 PM When Nothing works: Refractory RA / Treatment

Approach (Case Based Discussion)

7:05 PM - 7:13 PM Case 1

Speaker: Dr. Nilesh Nolkha

7:13 PM - 7:21 PM Case 2

Speaker: Dr. Sonal Mehra

7:21 PM - 7:30 PM Discussion

Moderator: Dr. Banwari Sharma



Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.













DAY 1: Friday 1st October, 2021 | Time 6.30 PM to 9.15 PM

Session 3		
Chairperson: Dr. Padmanabha Shenoy		
7:30 PM - 7:50 PM	Recent updates: Role of IL-6 Inhibition in Management of SSc-ILD Speaker: Dr. Santosh Mandal	
7:50 PM - 7:55 PM	Q & A Chairperson: Dr. Padmanabha Shenoy	
7:55 PM - 8:40 PM	Optimizing Anti-TNF alpha therapy in AS (Case based discussion)	
7:55 PM - 8:10 PM	Case 1 Speaker: Dr. Keerthi Talari	
8:10 PM - 8:25 PM	Case 2 Speaker: Dr. Pradip Kumar Sarma	
8.25 PM - 8.40 PM	Case based discussion Moderator: Dr. Vishad Vishwanath	
Session 4		
Chairperson: Dr. Yojana Gokhale		
8:40 PM - 9:00 PM	Expert opinion: SARS -COV2 context	
8:40 PM - 8:55 PM	Recommendations for management of RMDs & vaccination Speaker: Dr. Vineeta Shobha	
8:55 PM - 9:00 PM	Q & A Chairperson: Dr. Yojana Gokhale	
9:00 PM - 9:15 PM	Monoclonal Antibody usage in COVID 19 Speaker: Dr. Vasant Nagvekar (ID Specialist)	
9:15 PM - 9:20 PM	Q & A Chairperson: Dr. Yojana Gokhale	
9:20 PM - 9:25 PM	Thank you Mr. Vinayagam G.	

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.

Click here for registration





DSH, Cipla









DAY 2: Saturday 2nd October, 2021 | Time 6.30 PM to 9.15 PM

6:30 PM - 06:35 PM Welcome

Mr. Dipendra Singh

Senior Director Super Specialties, Cipla

Prof. Alakendu Ghosh

President, Indian Rheumatology Association (IRA)

Session 1

Chairperson: Dr. Debashish Danda		
6:35 PM - 7:00 PM	Role of IL-6 inhibitors in Large Vessel Vasculitis Speaker: Prof. Yoshikazu Nakaoka (Japan)	
7:00 PM - 7:05 PM	Q & A Chairperson: Dr. Debashish Danda	
7:05 PM -7:15 PM	Concluding Remarks & Discussion Chairperson: Dr. Debashish Danda	
	Moderator: Dr. Anand P. Rao	
7:15 PM - 8:05 PM	Challenging cases in treatment of JIA	
	Case based discussion	
7:15 PM - 7:27 PM	Case 1 Speaker: Dr. Manjari Agarwal	
7:27 PM - 7:39 PM	Case 2 Speaker: Dr. Vignesh Pandiarajan	
7:39 PM - 7:51 PM	Case 3 Speaker: Dr. T. Sathish	
7:51 PM - 8:05 PM	Case based discussion Moderator: Dr. Anand P. Rao	

Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.













DAY 2: Saturday 2nd October, 2021 | Time 6.30 PM to 9.15 PM

Session 2

Session 2			
Chairperson: Dr. Sanjiv Kapoor			
8:05 PM - 8:25 PM	Panel discussion: JAKi in RA: When, Who, Which & How?		
	Moderator: Dr. Vijay K. Rao Panellists: Dr. N. Raja, Dr. Avinash Jain Dr. Manish Dugar		
8:25 PM - 8:40 PM	Treating SLE: Targeting remission or low disease activity? Speaker: Dr. Himanshu Pathak		
8:40 PM - 8:45 PM	Q & A		

Session 3

Moderator: Dr. Ramesh Jois

3e55i0ii 3		
Chairperson: Dr. (Lt. General) Ved Chaturvedi		
8:45 PM - 9:10 PM	Articular manifestations in Psoriasis: Indian experiences (Crosstalk- Rheumat & Dermat)	
8:45 PM - 9:10 PM	DISCUSSION & Q & A Speaker: Dr. Uday Khopkar (Dermatologist) Chairperson: Dr. (Lt. General) Ved Chaturvedi	
9:10 PM - 9:15 PM	Thank you Dr. Sucheta Mehta Medical Affairs, Cipla	



Disclaimer: The Virtual session is a Knowledge sharing initiative by Arthritis & Rheumatic Diseases Foundation (ARDF) in association with Cipla, with the focus on continuous scientific upgradation, Participation in the virtual session is strictly restricted to Registered Medical Practitioners only.



